scholarly journals Revisiting the process of aggregate growth recovery after a capital destruction

2021 ◽  
Vol 68 ◽  
pp. 103293
Author(s):  
Jaime Alonso-Carrera ◽  
Stéphane Bouché ◽  
Carlos de Miguel
1994 ◽  
Vol 72 (04) ◽  
pp. 511-518 ◽  
Author(s):  
Valentine C Menys ◽  
Philip R Belcher ◽  
Mark I M Noble ◽  
Rhys D Evans ◽  
George E Drossos ◽  
...  

SummaryWe determined changes in platelet aggregability following cardiopulmonary bypass, using optical aggregometry to assess macroaggregation in platelet-rich plasma (PRP), and platelet counting to assess microaggregation both in whole blood and PRP. Hirudin was used as the anticoagulant to maintain normocalcaemia.Microaggregation (%, median and interquartile range) in blood stirred with collagen (0.6 µg/ml) was only marginally impaired following bypass (91 [88, 93] at 10 min postbypass v 95 (92, 96] prebypass; n = 22), whereas macroaggregation (amplitude of response; cm) in PRP stirred with collagen (1.0µg/ml) was markedly impaired (9.5 [8.0, 10.8], n = 41 v 13.4 [12.7,14.3], n = 10; p <0.0001). However, in PRP, despite impairment of macroaggregation (9.1 [8.5, 10.1], n = 12), microaggregation was near-maximal (93 [91, 94]), as in whole blood stirred with collagen. In contrast, in aspirin-treated patients (n = 14), both collagen-induced microaggregation in whole blood (49 [47, 52]) and macroaggregation in PRP (5.1 [3.8, 6.6]) were more markedly impaired, compared with control (both p <0.001).Similarly, in PRP, macroaggregation with ristocetin (1.5 mg/ml) was also impaired following bypass (9.4 [7.2, 10.7], n = 38 v 12.4 [10.0, 13.4]; p <0.0002, n = 20), but as found with collagen, despite impairment of macroaggregation (7.2 [3.5,10.9], n = 12), microaggregation was again near-maximal (96 [93,97]). The response to ristocetin was more markedly impared after bypass in succinylated gelatin (Gelo-fusine) treated patients (5.6 [2.8, 8.6], n = 17; p <0.005 v control), whereas the response to collagen was little different (9.3 v 9.5). In contrast to findings with collagen in aspirin-treated patients, the response to ristocetin was little different to that in controls (8.0 v 8.3). Impairment of macroaggregation with collagen or ristocetin did not correlate with the duration of bypass or the platelet count, indicating that haemodilution is not a contributory factor.In conclusion: (1) Macroaggregation in PRP, as determined using optical aggregometry, is specifically impaired following bypass, and this probably reflects impairment of the build-up of small aggregates into larger aggregates. (2) Impairment of aggregate growth and consolidation could contribute to the haemostatic defect following cardiac surgery.


1979 ◽  
Vol 57 (17) ◽  
pp. 1845-1848 ◽  
Author(s):  
R. C. France ◽  
M. L. Cline ◽  
C. P. P. Reid

Seventy-three isolates of eighteen ectomycorrhizal fungi were examined for their growth recovery after a 48-h exposure to −10 °C. Survival of all isolates was 97%. Recovery time to active growth varied between species and within species. Of surviving isolates, 72% initiated growth in less than 2 weeks after thawing. Growth rate was not affected for isolates exhibiting rapid recovery but was significantly lowered for isolates with recovery times of more than 5 weeks. Variation in growth form occurred with some species of Suillus and Xerocomus.


1997 ◽  
Vol 112 (6) ◽  
pp. 1839-1844 ◽  
Author(s):  
A Carroccio ◽  
G Iacono ◽  
P Lerro ◽  
F Cavataio ◽  
E Malorgio ◽  
...  

2018 ◽  
Vol 9 ◽  
Author(s):  
Vanessa Jane Melino ◽  
Alberto Casartelli ◽  
Jessey George ◽  
Thusitha Rupasinghe ◽  
Ute Roessner ◽  
...  

2018 ◽  
Vol 86 (5) ◽  
pp. 1827-1866 ◽  
Author(s):  
Jie Cai ◽  
Nan Li

Abstract The majority of innovations are developed by multi-sector firms. The knowledge needed to invent new products is more easily adapted from some sectors than from others. We study this network of knowledge linkages between sectors and its impact on firm innovation and aggregate growth. We first document a set of sectoral-level and firm-level observations on knowledge applicability and firms’ multi-sector patenting behaviour. We then develop a general equilibrium model of firm innovation in which inter-sectoral knowledge linkages determine the set of sectors a firm chooses to innovate in and how much R&D to invest in each sector. It captures how firms evolve in the technology space, accounts for cross-sector differences in R&D intensity, and describes an aggregate model of technological change. The model matches new observations as demonstrated by simulation. It also yields new insights regarding the mechanism through which sectoral fixed costs of R&D affect growth.


Sign in / Sign up

Export Citation Format

Share Document